Free Trial

This company has been marked as potentially delisted and may not be actively trading.

OvaScience (OVAS) Competitors

OvaScience logo

OVAS vs. ZYME, CALT, SBTX, ETHZ, AVTE, NLTX, BIOA, VIRI, WHWK, and SPRB

Should you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), Silverback Therapeutics (SBTX), Flag Ship Acquisition (ETHZ), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), and Spruce Biosciences (SPRB).

OvaScience vs. Its Competitors

OvaScience (NASDAQ:OVAS) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

22.5% of OvaScience shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 7.4% of OvaScience shares are held by insiders. Comparatively, 1.9% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Zymeworks had 13 more articles in the media than OvaScience. MarketBeat recorded 13 mentions for Zymeworks and 0 mentions for OvaScience. Zymeworks' average media sentiment score of 0.52 beat OvaScience's score of 0.00 indicating that Zymeworks is being referred to more favorably in the news media.

Company Overall Sentiment
OvaScience Neutral
Zymeworks Positive

OvaScience has higher earnings, but lower revenue than Zymeworks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OvaScience$290K1,268.88-$50.97MN/AN/A
Zymeworks$76.30M17.84-$122.69M-$0.97-18.67

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OvaScience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Zymeworks
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50

Zymeworks has a net margin of -59.96% compared to OvaScience's net margin of -10,128.37%. Zymeworks' return on equity of -21.59% beat OvaScience's return on equity.

Company Net Margins Return on Equity Return on Assets
OvaScience-10,128.37% -47.06% -42.39%
Zymeworks -59.96%-21.59%-16.52%

OvaScience has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.

Summary

Zymeworks beats OvaScience on 9 of the 13 factors compared between the two stocks.

Get OvaScience News Delivered to You Automatically

Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OVAS vs. The Competition

MetricOvaSciencePharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$367.97M$787.62M$6.05B$10.30B
Dividend YieldN/A4.84%5.73%4.82%
P/E RatioN/A1.2885.3127.10
Price / Sales1,268.8829.85601.46133.29
Price / CashN/A17.6425.7730.18
Price / Book5.717.5412.676.69
Net Income-$50.97M-$7.59M$3.32B$276.55M

OvaScience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OVAS
OvaScience
N/A$10.27
-4.7%
N/A+902.0%$367.97M$290K0.00N/A
ZYME
Zymeworks
0.0668 of 5 stars
$16.92
+1.4%
N/AN/A$1.27B$76.30M-17.44460News Coverage
Analyst Upgrade
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
SBTX
Silverback Therapeutics
N/A$11.11
+7.6%
N/A-22.0%$400.60MN/A-4.5983High Trading Volume
ETHZ
Flag Ship Acquisition
N/A$2.19
-5.6%
N/AN/A$360.10MN/A-0.157Gap Up
AVTE
Aerovate Therapeutics
N/A$9.08
+0.4%
N/A-87.8%$263.18MN/A-3.0420High Trading Volume
NLTX
Neoleukin Therapeutics
N/A$23.47
+1.6%
N/A-38.9%$220.57MN/A-7.5590High Trading Volume
BIOA
BioAge Labs
0.182 of 5 stars
$5.45
-3.9%
N/AN/A$195.38MN/A0.00N/A
VIRI
Virios Therapeutics
N/A$6.38
-5.6%
N/A+30.3%$122.87MN/A-23.635Gap Down
WHWK
Whitehawk Therapeutics
0.9943 of 5 stars
$2.17
+1.9%
N/AN/A$102.27M$21.60M-36.1721
SPRB
Spruce Biosciences
0.6543 of 5 stars
$175.31
+9.5%
$131.25
-25.1%
+421.0%$98.17M$4.91M-2.0320Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:OVAS) was last updated on 10/13/2025 by MarketBeat.com Staff
From Our Partners